FocusOn Neurology
  • Multiple Sclerosis
  • Migraine Research Library
  • LGS & Dravet Syndrome
  • Tardive Dyskinesia
  • Myasthenia Gravis
  • Neurofibromatosis
  • hATTR-PN
  • MDA 2024
  • CIDP Awareness Month
  • Alzheimer's Awareness Month
  • Anticoagulation Reversal Knowledge & Learning Center
  • PNS 2024 Annual Meeting Highlights
  • Parkinson's Disease
  • AES Annual Meeting 2025
  • Epilepsy Knowledge Hub
  • Stroke Awareness Month
  • Multiple Sclerosis
  • Migraine Research Library
  • LGS & Dravet Syndrome
  • Tardive Dyskinesia
  • Myasthenia Gravis
  • Neurofibromatosis
  • hATTR-PN
  • MDA 2024
  • CIDP Awareness Month
  • Alzheimer's Awareness Month
  • Anticoagulation Reversal Knowledge & Learning Center
  • PNS 2024 Annual Meeting Highlights
  • Parkinson's Disease
    • Peer-reviewed articles
    • Supplemental educational content
    • Test Your Knowledge
  • AES Annual Meeting 2025
  • Stroke Awareness Month

Advanced Search

Advanced Search

  • Featured:
  • Epilepsy Knowledge Hub

Risk of Myasthenia Gravis Exacerbation During Pregnancy and Postpartum

June 2026

Back to Myasthenia Gravis Peer-reviewed articles

Read Full Article

Abstract

Background and Objectives

The impact of pregnancy on the clinical course of myasthenia gravis (MG) remains uncertain, with existing evidence mainly derived from small case series. Using nationwide longitudinal register data, we aimed to assess the risk of MG exacerbation during pregnancy and up to 1 year postpartum.

Methods

In this population-based cohort study, we included women with MG recorded in the Swedish National MG Register who had singleton pregnancies documented in the Medical Birth Register after MG diagnosis (1987–2019). The exposure was pregnancy, and the outcome was MG exacerbation. The primary outcome measure was hospital admissions with MG during pregnancy and the postpartum year, compared with the year preceding pregnancy. Cox proportional hazards models estimated hazard ratios (HRs), adjusting for disease duration and prior thymectomy. The secondary outcome measure was changes in immunosuppressive MG medications during pregnancy and postpartum.

Results

We identified 112 women with MG (median age 30 years) with 176 singleton pregnancies. During pregnancy, women were not more likely to be hospitalized for MG than in the prepregnancy year (HR 0.74, 95% CI 0.39–1.41), and there was no increased risk of longer hospital admissions (HR 0.83, 95% CI 0.36–1.88). The postpartum period was associated with an increased risk of prolonged MG admissions during the first 3 months (HR 5.02, 95% CI 1.66–15.24), with a similar risk observed throughout the first 12 months postpartum (HR 4.52, 95% CI 1.26–16.14). During pregnancy, immunosuppressive MG medications were reduced or discontinued in 13 pregnancies and increased in 6. Postpartum, medications were initiated or escalated in 10 pregnancies and reduced in none. The risk of prolonged MG admissions was higher in periods outside of pregnancy compared with the prepregnancy year (HR 2.95, 95% CI 0.84–10.43), suggesting that women conceive during periods of relative disease stability.

Discussion

Pregnancy was not associated with an increased risk of MG exacerbation. The postpartum period was linked to more severe or prolonged exacerbations in a minority of women, highlighting the importance of close monitoring after delivery. Milder exacerbations not requiring hospitalization or clear medication escalation may have been underestimated, underscoring the need for larger prospective international studies that include detailed clinical data.

Share

Modal body text goes here.

FocusOn logo
  • Articles
  • Multimedia
  • Blog
  • Resources
  • About FocusOn
  • Privacy Policy
  • Terms of Use

© 2026 Wolters Kluwer. All right reserved.

Your Privacy

To give you the best possible experience we use cookies and similar technologies. We use data collected through these technologies for various purposes, including to enhance website functionality, remember your preferences, show the most relevant content, and show the most useful ads. You can select your preferences by clicking the link. For more information, please review our Privacy and Cookie Policy.

|
|

Cookie Policy

Information about our use of cookies

Wolters Kluwer ("we" or "us") wants to inform you about the ways we process your personal information. In this Privacy & Cookie Notice we explain what personal information we collect, use and disclose.

Personal information means any data relating to an individual who can be identified, directly or indirectly, based on that information. This may include information such as names, contact details, (online) identification data, online identifiers, or other characteristics specific to that individual.

Read More